Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non-Current Deferred Tax Liability came in at $7.0 billion in Q1 2026, up 188.76% year-on-year from $2.4 billion in Q1 2025, and up 3.24% quarter-over-quarter from $6.8 billion in Q4 2025.

Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $7.0 billion for Q1 2026.

  • Non-Current Deferred Tax Liability for Q1 2026 came in at $7.0 billion, up 188.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 billion (up 188.76% YoY), and the FY2025 annual result was $6.8 billion, up 177.41% from the prior year.
  • Non-Current Deferred Tax Liability came in at $7.0 billion for Q1 2026 at Johnson & Johnson, up from $6.8 billion in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.5 billion in Q1 2022 to a low of $2.4 billion in Q1 2025.
  • The 5-year median for Non-Current Deferred Tax Liability is $3.9 billion (2023), against an average of $4.4 billion.
  • Across the five-year window, Non-Current Deferred Tax Liability plunged 46.97% in 2023 and soared 188.76% in 2026, its largest moves.
  • Johnson & Johnson's Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then sank by 35.44% to $3.2 billion in 2023, then retreated by 23.33% to $2.4 billion in 2024, then surged by 177.41% to $6.8 billion in 2025, then rose by 3.24% to $7.0 billion in 2026.
  • The last three Non-Current Deferred Tax Liability figures came in at $7.0 billion (Q1 2026), $6.8 billion (Q4 2025), and $6.0 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 7.01 Bn
Mar 29, 2026 7.01 Bn
Dec 28, 2025 6.79 Bn
Dec 28, 2025 6.79 Bn
Sep 28, 2025 5.99 Bn
Sep 28, 2025 5.99 Bn
Jun 29, 2025 3.80 Bn
Jun 29, 2025 3.80 Bn
Mar 30, 2025 2.43 Bn
Mar 30, 2025 2.43 Bn
Dec 29, 2024 2.45 Bn
Dec 29, 2024 2.45 Bn
Sep 29, 2024 2.95 Bn
Sep 29, 2024 2.95 Bn
Jun 30, 2024 2.64 Bn
Jun 30, 2024 2.64 Bn
Mar 31, 2024 3.17 Bn
Mar 31, 2024 3.17 Bn
Dec 31, 2023 3.19 Bn
Dec 31, 2023 3.19 Bn